1SD rule
1SDルール

Under the DPC (diagnosis procedure combination) system (診断群分類包括評価制度), a fixed amount of reimbursement is determined for each disease (combination of the diagnosis and procedures). However, patients who need high-priced new drugs whose cost exceeds the average of costs for existing...

To read the full story

LEXICON

Elective Care Scheme for LLPs長期収載品選定療養制度
July 19, 2024
G1/G2 RuleG1/G2ルール
March 9, 2018
New PMP Criteria新薬創出加算の新要件
March 9, 2018
Cost-Based Method原価計算方式
July 27, 2017
Sakigake Designation Scheme先駆け審査指定制度
August 17, 2016

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…